Gilead acquired Immunomedics in 2020 for US $21 Bn. The main drug the latter had was Trodelvy which was approved by FDA for use in cancer treatment.
The interesting bit for me from a Bloomberg article today was that the Gilead CEO called Trodelvy as “pipeline in a product” which could have a wide variety of uses. I think this is a good way of marketing Zantrene to BP
(this is a cooler title than just as a multi-use drug- we are selling you a pipeline!)
Industry news, page-646
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
0.000(0.00%) |
Mkt cap ! $273.4M | |||
| Open | High | Low | Value | Volume |
| $1.61 | $1.66 | $1.61 | $197.3K | 121.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2131 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 473 | 1 |
View Market Depth
| Last trade - 13.27pm 29/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |